Live Breaking News & Updates on Dermtech Melanoma Test

Stay updated with breaking news from Dermtech melanoma test. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

DermTech, Inc. (NASDAQ:DMTK) Sees Large Decline in Short Interest

DermTech, Inc. (NASDAQ:DMTK – Get Free Report) saw a large drop in short interest during the month of May. As of May 15th, there was short interest totalling 2,850,000 shares, a drop of 7.8% from the April 30th total of 3,090,000 shares. Based on an average daily volume of 599,200 shares, the short-interest ratio is […] ....

United States , Quantum Private Wealth , Texas Capital Bank Wealth Management Services Inc , Dermtech Company Profile , Dermtech Inc , Savant Capital , Get Free Report , Private Wealth , Capital Bank Wealth Management Services Inc , Lake Street Capital , Tech Stock Down , Dermtech Melanoma Test , Dermtech Daily ,

DermTech's (DMTK) Equal Weight Rating Reiterated at Stephens

DermTech's (DMTK) Equal Weight Rating Reiterated at Stephens
themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.

United States , Savant Capital , Texas Capital Bank Wealth Management Services Inc , Dermtech Inc , Quantum Private Wealth , Dermtech Company Profile , Free Report , Get Free Report , Capital Bank Wealth Management Services Inc , Private Wealth , Dermtech Melanoma Test , Dermtech Daily ,

Lake Street Capital Reiterates "Hold" Rating for DermTech (NASDAQ:DMTK)

DermTech (NASDAQ:DMTK – Get Free Report)‘s stock had its “hold” rating restated by investment analysts at Lake Street Capital in a research report issued on Friday, Benzinga reports. They currently have a $0.63 price target on the stock. Lake Street Capital’s target price suggests a potential downside of 2.17% from the stock’s previous close. A […] ....

United States , Dermtech Inc , Jpmorgan Chase Co , Centaurus Financial Inc , Charles Schwab Investment Management Inc , Swiss National Bank , Get Free Report , Lake Street Capital , Street Capital , Schwab Investment Management , National Bank , Dermtech Melanoma Test , Dermtech Daily , Nasdaq Dmtk , Reiterated Rating ,

DermTech (NASDAQ:DMTK) Rating Reiterated by Stephens

DermTech (NASDAQ:DMTK – Get Free Report)‘s stock had its “equal weight” rating reaffirmed by equities researchers at Stephens in a research note issued on Friday, Benzinga reports. They presently have a $1.50 price objective on the stock. Stephens’ price target points to a potential upside of 132.92% from the company’s previous close. Separately, BTIG Research […] ....

United States , Dermtech Inc , Swiss National Bank , Dermtech Company Profile , Centaurus Financial Inc , Charles Schwab Investment Management Inc , Jpmorgan Chase Co , Get Free Report , Schwab Investment Management , National Bank , Dermtech Melanoma Test , Dermtech Daily , Nasdaq Dmtk , Reiterated Rating ,

DermTech (NASDAQ:DMTK) Trading Down 0.9%

DermTech, Inc. (NASDAQ:DMTK – Get Free Report) fell 0.9% on Tuesday . The company traded as low as $0.60 and last traded at $0.61. 48,834 shares were traded during mid-day trading, a decline of 85% from the average session volume of 321,284 shares. The stock had previously closed at $0.62. Analyst Upgrades and Downgrades Separately, […] ....

United States , Dermtech Company Profile , Jpmorgan Chase Co , Swiss National Bank , Charles Schwab Investment Management Inc , Centaurus Financial Inc , Dermtech Inc , Get Free Report , Schwab Investment Management , National Bank , Dermtech Melanoma Test , Dermtech Daily , Nasdaq Dmtk ,